Synaptic vesicle glycoprotein 2A (SV2A) is expressed ubiquitously in neurons of the central nervous system, and is the binding target of the anti-epileptic drug levetiracetam. Because of the availability of positron emission tomography (PET) ligands targeting SV2A, there is increasing enthusiasm on the use of SV2A PET to study a variety of neuropsychiatric diseases. This review discusses the recent development of radioligands for PET imaging of SV2A and their potential use in the research and diagnosis of CNS diseases.
Keywords: Alzheimer’s disease; Autism spectrum disorder; Depression; Epilepsy; Huntington’s disease; Multiple sclerosis; PET; Parkinson’s disease; SV2A; Schizophrenia; Stroke; Synaptic density.
Copyright © 2018 Elsevier B.V. All rights reserved.